
Will orphan drugs become less important to large pharma growth in the future? Orphan drugs (which target patient populations in the US under 200,000) are still key drivers for pharma top-lines #orphandrug It's interesting to see that for some companies, the share of revenue from orphan drugs is declining. LOEs are also driving absolute declines for $BMY and $PFE The largest orphan company $VRTX is diversifying away from orphan only revenue #learnbiotechinvesting #biotech #investing #BiotechPrometheus






















